多西他赛或伊立替康联合顺铂、氟尿嘧啶治疗晚期胃癌的疗效比较

目的观察多西他赛或伊立替康联合顺铂、氟尿嘧啶治疗晚期胃癌的疗效以及安全性。方法 31例病例随机分为多西他赛、顺铂联合氟尿嘧啶组(DCF,16例)和伊立替康、顺铂联合氟尿嘧啶组(ICF,15例);DCF组:Doc 60mg/m2,静脉滴注,第1天;DDP75mg/m2,分3天静脉滴注;5-FU 500mg/m2,静脉滴注第1～5天。ICF组:CPT-1165mg/m2,静脉滴注,第1、8天;DDP、5-FU用量用法同DCF组;每3周重复,直至疾病进展或出现不可耐受毒副反应,最多6个周期。每2周期评价疗效。化疗结束后每月随访一次进行生存分析。结果 DCF组有效率40%(6/15),ICF组38.46%(5/13()χ2=0.007,P=0.934);DCF组中位生存期9.5个月,ICF组10个月(χ2=0.39,P=0.5336);1年生存率DCF组30.68%,ICF组26.43%。结论两种方案治疗的近远期疗效相近,主要不良反应经对症处理后均缓解,无治疗相关死亡,是晚期胃癌的一线有效治疗方案,值得临床继续观察疗效。

Docetaxel or Irinotecan Plus DDP, 5-Fu Comparison in Patients with Advanced Gastric Cancer

Objective To compare efticacies and safeties of 2 different treatments of docetaxolor irinotecan plus DDP,5-Fu for advanced gastric patients. Methods 31 patients were randomly divided into docetaxol, DDP plus 5-Fu regime（DCF, 16 patients）and irinotecan, DDP plus 5-Fu regime（ICF, 19 patients）.DCF group： Doc 60mg/m2, intravenously dl; DDP 75mg/m2, intravenously dl-3; 5-FU 500mg/m：, intravenously d]-5. ICF Group： CPT-11 65 mg/m~, intravenously dl,8; DDP ,5-FU same with DCF group. Repeated every 3 weeks until disease progression or intolerable toxicity, up to 6 cycles. Results Total response rate of DCF and ICF were 40% and 38.46% （P=-0.934）. The median survival of DCF and ICF groups were 9.5 and 10 months （P=-0.5336）. 1 year survival rate of DCF and ICF groups were 30.68% and 26.43%（22=0.383,P〉0.05）. Conclusion Both DCF and ICF groups are effective, and the main adverse event is tolerable after therapy. It can be applied to the advanced gastric cancer patients in clinical firstly and effectively.